Skip to Main Content

+

  • • Upper GI endoscopic or contrast radiographic evidence of duodenal tumor

++

Epidemiology

++

Adenomas

+

  • • Sessile or pedunculated

    • May be associated with familial adenomatous polyposis

    Tubular: Low malignant potential

    Villous

    • -High malignant risk

      -30% of those > 3 cm with malignant focus

      -Often periampullary

    Brunner gland

    • -Hyperplasia of exocrine glands

      -Often asymptomatic

++

Gastrointestinal Stromal Tumors (GIST)

+

  • • Difficult to distinguish benign from malignant on histologic studies

++

Neuroendocrine (Carcinoid) Tumors

+

  • • Often endocrinologically active

++

Hamartomas

+

  • • Associated with Peutz-Jeghers syndrome

    • Rare malignant potential

++

Lipomas

+

  • • No malignant potential

++

Symptoms and Signs

+

  • • Gastric outlet obstruction

    • Biliary obstruction and jaundice

    • Upper GI bleeding

    • Carcinoid syndrome (flushing, diarrhea) if hepatic metastases are present

++

Laboratory Findings

+

  • • Neuroendocrine tumors: Elevated serum serotonin, somatostatin or gastrin; urine 5-hydroxyindoleacetic acid (5-HIAA)

    • Anemia

++

Imaging Findings

+

  • • Duodenal tumor evident on upper GI endoscopy or contrast radiography

+

  • • Duodenal mass

    • Often asymptomatic

    • CT scan may help differentiate tumor type

++

Rule Out

+

  • • Malignant duodenal tumors or focus of malignancy in a benign tumor

+

  • • Symptoms and signs of duodenal mass

    • Upper GI endoscopy or contrast radiography

    • Endoscopic biopsy or polpectomy

    • CT scan to distinguish tumor type and rule out metastases

++

When to Admit

+

  • • Severe gastric obstruction prohibiting eneteral intake

    • GI bleeding

    • Biliary obstruction

+

  • • Endoscopic removal if possible

++

Surgery

++

Indications

+

  • • Failure of endoscopic removal

    • If malignant, pancreaticoduodenectomy usually indicated

++

Medications

+

  • • GIST: Imatinib mesylate.

    • Carcinoid syndrome: Octreotide.

++

Treatment Monitoring

+

  • • Repeated interval upper GI endoscopy or contrast radiography

++

Complications

+

  • • Bleeding

    • Gastric outlet obstruction

    • Biliary obstruction

++

Prognosis

+

  • • If benign, most tumors cured by removal

    • If malignant, 60% overall 5-year survival

++

References

Egberts JH. et al. Small bowel cancer: single-centre results over a period of 12 years. Hepato-Gastroenterology, 2007;54(73):129-34.  [PubMed: 17419246]
Oka K. et al. Aggressive carcinoid tumors arising in the duodenum, ileum, and rectum with liver metastasis: a report of three cases. Hepato-Gastroenterology, 2008;55(86-87):1660-3.

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.